Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial

BACKGROUND Fibrocytes are BM-derived circulating cells that traffic to the injured lungs and contribute to fibrogenesis. The mTOR inhibitor, sirolimus, inhibits fibrocyte CXCR4 expression, reducing fibrocyte traffic and attenuating lung fibrosis in animal models. We sought to test the hypothesis tha...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Diana C. Gomez-Manjarres, Dierdre B. Axell-House, Divya C. Patel, John Odackal, Victor Yu, Marie D. Burdick, Borna Mehrad
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Clinical investigation 2023-04-01
Edice:	JCI Insight
Témata:	Pulmonology
On-line přístup:	https://doi.org/10.1172/jci.insight.166901
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!